FINANCES: What resources were available to support the national program in the past?

OUTCOME: How many people received the treatment and prevention services that they need?

IMPACT: What is the trend among people who continue to fall ill or die? (actual and hypothetical in the absence of program)

Historical investments by funding source (2012-2023)


Global Fund investments: 2017-2019 Allocation period Tuberculosis disbursements: \$288m

2020-2022 Allocation period Tuberculosis disbursements: \$226m TB/HIV disbursements: \$23.3m

In 2021-2023, 79% of NSP need was funded.


TB/HIV disbursements: \$13.9m

TB financing¹



Investments by funding source and intervention (2024-2026)²

Total amount in budget: \$1.78b




TB Human Rights

\$0.3m


Not in graph

Global Fund Results (2023)


People with TB treated: People with drug-resistant TB 2.38m on treatment: 49.6k




Bacteriologically confirmed pulmonary TB cases tested for rifampicin resistance



TB treatment outcomes





HIV+ TB patients on ART:


34.3k

TB deaths (excluding HIV+)

Change in TB deaths (excluding HIV+):

23% reduction from 2012 to 2022

58% reduction from 2000 to 2022




New TB cases (all forms)

Change in TB cases:

14% reduction from 2012 to 2022

17% reduction from 2000 to 2022



Detailed notes are available on the separate Explanatory Notes page

 $(https://www.theglobalfund.org/media/7871/other_countryresultsprofileexplanatory_notes_en.pdf)$

Source: Data submitted by the country as part of their Funding Request for 2020-22 allocation period; GF detailed budget data. These data sources contain a mix of historical figures and projections.

²Source: Data submitted by the country as part of their Funding Request for 2023-25 allocation period; GF detailed budget data. These data sources contain a mix of historical figures and projections.